---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-005189"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T19:08:05.191218+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MiNK reports Q2 2023 net loss $6.2M; cash low at $10.6M; Phase 2 gastric trial planned

## Summary
- Six-month 2023 net loss $11.9M ($0.35/share) vs $13.9M ($0.41) in prior year period.
- Cash $10.6M at June 30, 2023, down from $14.9M at March 31, 2023; Q2 cash used $4.1M.
- Externally funded randomized Phase 2 trial in 2L gastric cancer planned at MSKCC; IND for MiNK-215 on track for 2024.
- AgenT-797 showed 75% survival in COVID-19 ARDS patients vs 30% in-hospital controls; dosed up to 1B cells.

## SEC filing metadata
- accession: 0001171843-23-005189
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000117184323005189/0001171843-23-005189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000117184323005189/f8k_081023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-005189
- JSON: https://secwatch.observer/filing/0001171843-23-005189.json
- Plain text: https://secwatch.observer/filing/0001171843-23-005189.txt

## Key facts
- Earnings Releases
  MiNK Therapeutics, Inc. reported the second quarter 2023 results: net income Net loss for the six-months ended June 30, 2023 was $11.9 million, or $0.35 per share.
  - Period: the second quarter 2023
  - Net income: Net loss for the six-months ended June 30, 2023 was $11.9 million, or $0.35 per share
  - Result: reported results
  source text: On August 10, 2023, MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840229/000117184323005189/0001171843-23-005189-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.